Central Retinal Vein Occlusion - Pipeline Insight, 2024

This “Central Retinal Vein Occlusion - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Central Retinal Vein Occlusion pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Central Retinal Vein Occlusion Understanding

Central Retinal Vein Occlusion: Overview

Retinal vein occlusion (RVO) is the second most common retinal vascular disease and is a common loss of vision in older patients. There are two types of RVO: Branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). Central retinal vein occlusion is an occlusion of the main retinal vein posterior to the lamina cribrosa of the optic nerve and is typically caused by thrombosis. Central retinal vein occlusion is further divided into two categories: non-ischemic (perfused) and ischemic (nonperfused). Non-ischemic CRVO is the most common, accounting for about 70% of cases. Best-corrected visual acuity (BCVA) is often better than 20/200. This activity outlines the evaluation and management of central retinal vein occlusion (CRVO) and reviews the role of the interprofessional team in improving care for patients with this condition. A primary risk factor for the development of central retinal vein occlusion is age, with 90% of patients older than 50 years old. Systemic arterial hypertension, open-angle glaucoma, diabetes mellitus, and hyperlipidemia have all been implicated as other primary risk factors for central retinal vein occlusion. No totally effective medical treatment is available for either the prevention or treatment of central retinal vein occlusion. In patients with central retinal vein occlusion, vascular endothelial growth factor (VEGF) is elevated; this leads to swelling as well as new vessels (neovascularization) that are prone to bleeding. Often treatment involves intravitreal injections of an anti-VEGF drug to reduce the new blood vessel growth and swelling.

Central Retinal Vein Occlusion - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Central Retinal Vein Occlusion pipeline landscape is provided which includes the disease overview and Central Retinal Vein Occlusion treatment guidelines. The assessment part of the report embraces, in depth Central Retinal Vein Occlusion commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Central Retinal Vein Occlusion collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Central Retinal Vein Occlusion.
• In the coming years, the Central Retinal Vein Occlusion market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics that are working to assess challenges and seek opportunities that could influence Central Retinal Vein Occlusion R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• A detailed portfolio of major pharma players who are involved in fueling the Central Retinal Vein Occlusion treatment market. Several potential therapies for Central Retinal Vein Occlusion are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Central Retinal Vein Occlusion market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Central Retinal Vein Occlusion) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Central Retinal Vein Occlusion Emerging Drugs Chapters

This segment of the Central Retinal Vein Occlusion report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Central Retinal Vein Occlusion Emerging Drugs

610: 3SBio Recombinant Anti-IL5 Humanized Monoclonal Antibody Injection (hereinafter referred to as 610) is a new recombinant humanized IgG1 type 1 monoclonal antibody independently developed by our company. 610 blocks IL5 from binding to its receptor by binding to IL 5, thus playing a role in inhibiting eosinophil proliferation, differentiation and activation. Currently, it is being evaluated in Phase II stage of clinical trial evaluation to treat Central Retinal VeinOcclusion.

GS-101 (Aganirsen): Gene Signal Gene Signal is currently developing aganirsen GS-101 (an antisense oligonucleotide or short naturally occurring DNA strand). GS-101 is a topical medication in the form of eye drops, and is currently being researched for the management of excessive vascular growth in the cornea, also known as “neovascularisation”. GS-101 is a copy of a naturally occurring human gene and acts by inhibiting the expression of IRS-1, a protein required for the formation and growth of new blood vessels. By blocking the expression of this protein in pro-angiogenic conditions (in this case, those with excessive vascular growth), GS-101 inhibits and regresses corneal neovascularisation, which interferes with vision and may be the cause of graftrejection.

Central Retinal Vein Occlusion: Therapeutic Assessment

This segment of the report provides insights about the different Central Retinal Vein Occlusion drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Central Retinal Vein Occlusion

There are approx. 3+ key companies which are developing the therapies for Central Retinal Vein Occlusion. The companies which have their Central Retinal Vein Occlusion drug candidates in the most advanced stage, i.e. phase II include, 3SBio.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Central Retinal Vein Occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Central Retinal Vein Occlusion: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Central Retinal Vein Occlusion therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Central Retinal Vein Occlusion drugs.

Central Retinal Vein Occlusion Report Insights

• Central Retinal Vein Occlusion Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Central Retinal Vein Occlusion Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Central Retinal Vein Occlusion drugs?
• How many Central Retinal Vein Occlusion drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Central Retinal Vein Occlusion?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Central Retinal Vein Occlusion therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Central Retinal Vein Occlusion and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• 3SBio
• Gene Signal
• Celon pharma
• The Emmes Company, LLC

Key Products

• 610
• GS-101 (Aganirsen)
• Ranibizumab biosimilar
• Autologous Bone Marrow CD34+ Stem Cells